Literature DB >> 8762029

Comparison of the effects of class I anti-arrhythmic drugs, cibenzoline, mexiletine and flecainide, on the delayed rectifier K+ current of guinea-pig ventricular myocytes.

D W Wang1, T Kiyosue, T Sato, M Arita.   

Abstract

The effect of class I anti-arrhythmic drugs, cibenzoline, mexiletine and flecainide, on the delayed rectifier potassium current (IK) in guinea-pig ventricular myocytes was studied using whole cell voltage clamp techniques and under blockade of the L-type calcium current by 5 microM nitrendipine. IK consisted of two different current systems, as reported by Sanguinetti and Jurkiewicz (1990), i.e. an E4031-sensitive rapidly activating component (IKr) with a strong inward-going rectification property and an E4031-insensitive slowly activating component (IKs) with little rectification. Cibenzoline (30 microM) decreased both IKr and IKs while flecainide (10 and 30 microM) decreased the IKr exclusively. Mexiletine (30 microM), in contrast, affected neither IKr nor IKs. Since the inhibition of IK(r) and/or IKs prolongs duration of action potentials and refractory periods, class I drugs which also possess the class III effect may have additional effects in treating certain re-entrant arrhythmias.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8762029     DOI: 10.1006/jmcc.1996.0084

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  17 in total

1.  Inhibitory effects of JTV-519, a novel cardioprotective drug, on potassium currents and experimental atrial fibrillation in guinea-pig hearts.

Authors:  H Nakaya; Y Furusawa; T Ogura; M Tamagawa; H Uemura
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  A computational model to predict the effects of class I anti-arrhythmic drugs on ventricular rhythms.

Authors:  Jonathan D Moreno; Z Iris Zhu; Pei-Chi Yang; John R Bankston; Mao-Tsuen Jeng; Chaoyi Kang; Lianguo Wang; Jason D Bayer; David J Christini; Natalia A Trayanova; Crystal M Ripplinger; Robert S Kass; Colleen E Clancy
Journal:  Sci Transl Med       Date:  2011-08-31       Impact factor: 17.956

3.  Bepridil differentially inhibits two delayed rectifier K(+) currents, I(Kr) and I(Ks), in guinea-pig ventricular myocytes.

Authors:  J C Wang; T Kiyosue; K Kiriyama; M Arita
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

4.  Inhibitory effects of aprindine on the delayed rectifier K+ current and the muscarinic acetylcholine receptor-operated K+ current in guinea-pig atrial cells.

Authors:  Y Ohmoto-Sekine; H Uemura; M Tamagawa; H Nakaya
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

Review 5.  Pathophysiology of the cardiac late Na current and its potential as a drug target.

Authors:  Jonathan D Moreno; Colleen E Clancy
Journal:  J Mol Cell Cardiol       Date:  2011-12-16       Impact factor: 5.000

6.  Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening.

Authors:  Jonathan D Moreno; Pei-Chi Yang; John R Bankston; Eleonora Grandi; Donald M Bers; Robert S Kass; Colleen E Clancy
Journal:  Circ Res       Date:  2013-07-29       Impact factor: 17.367

7.  Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine.

Authors:  Ashok A Paul; Harry J Witchel; Jules C Hancox
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

Review 8.  Congenital long QT syndromes: prevalence, pathophysiology and management.

Authors:  Alon Barsheshet; Olena Dotsenko; Ilan Goldenberg
Journal:  Paediatr Drugs       Date:  2014-12       Impact factor: 3.022

9.  A novel and lethal de novo LQT-3 mutation in a newborn with distinct molecular pharmacology and therapeutic response.

Authors:  John R Bankston; Minerva Yue; Wendy Chung; Meghan Spyres; Robert H Pass; Eric Silver; Kevin J Sampson; Robert S Kass
Journal:  PLoS One       Date:  2007-12-05       Impact factor: 3.240

10.  Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide.

Authors:  Dario Melgari; Yihong Zhang; Aziza El Harchi; Christopher E Dempsey; Jules C Hancox
Journal:  J Mol Cell Cardiol       Date:  2015-07-06       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.